Literature DB >> 1497358

Cutaneous reactions to granulocyte-monocyte colony-stimulating factor.

D R Mehregan1, A F Fransway, J H Edmonson, K M Leiferman.   

Abstract

BACKGROUND AND
DESIGN: Granulocyte-monocyte colony-stimulating factor (GMCSF) is a hematopoietic growth factor that stimulates the proliferation and differentiation of neutrophils, eosinophils, and monocytes. We reviewed the cutaneous reactions that developed in 26 patients who received GMCSF as part of a chemotherapeutic protocol.
RESULTS: Fourteen patients developed immediate localized angioedematous reactions at the subcutaneous GMCSF injection site, and 21 developed generalized cutaneous reactions. Four biopsy specimens were obtained from three patients who had generalized erythrodermic reactions. All specimens showed perivascular and periadnexal lymphocytic inflammation in the dermis, and two showed perivascular and periadnexal eosinophilia. Staining for eosinophil granule major basic protein showed infiltration by eosinophils and extracellular deposition of major basic protein in three specimens from two patients with eosinophilia. Extracellular deposition of neutrophil elastase and mast cell tryptase was minimal.
CONCLUSIONS: Cutaneous reactions are prominently associated with GMCSF administration. Eosinophils, known to release toxic products after being activated, may have a role in these skin reactions through stimulation by GMCSF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497358

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  3 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?

Authors:  G J Locker; I Simonitsch; R M Mader; E Warlamides; M F Gnant; R Jakesz; H Rainer; G G Steger
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

3.  Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

Authors:  C T Kouroukis; S Chia; S Verma; D Robson; C Desbiens; C Cripps; J Mikhael
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.